EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
Latest EULAR Recommendations
EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update
2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome
EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis
Spondyloarthritis:HLA-B27, axial spondyloarthritis and survival
7 September 2023
Rheumatoid arthritis:Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study
24 July 2023
Rheumatoid arthritis:Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial
9 July 2023
Autoinflammatory disorders:Single-cell resolution of longitudinal blood transcriptome profiles in rheumatoid arthritis, systemic lupus erythematosus and healthy control pregnancies
1 December 2023
Vasculitis:Clonal haematopoiesis across the age spectrum of vasculitis patients with Takayasus arteritis, ANCA-associated vasculitis and giant cell arteritis
29 November 2023
Images in rheumatology:Vasculitis that did not read the books
28 November 2023
Rheumatoid arthritis:In early rheumatoid arthritis, anticitrullinated peptide antibodies associate with low number of affected joints and rheumatoid factor associates with systemic inflammation
27 November 2023
Early arthritis:Rheuma-VOR study: optimising healthcare of rheumatic diseases by multiprofessional coordinating centres
27 November 2023
The EULAR Standing Committees regularly establish and publish recommendations for the treatment of various rheumatic disorders. Each of these recommendations is developed by a group of specialists in their field.
All EULAR recommendations are free to access.
Each recommendation also has an accompanying lay summary, which is also free to access.
Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies
Conclusion: At Week 52, dual inhibition of IL-17A and IL-17F with BKZ resulted in sustained efficacy across the axSpA spectrum; the safety profile was consistent with the known safety of BKZ.Find out more
Perth and KinrossNHS Tayside Consultant in Child & Adolescent Psychiatry 40 Hours per week We have an exciting opportunity available in one of the UK’s most up an...
Recruiter: NHS Tayside
Salaried General Practitioner
Richmond, North YorkshireWe are looking for an enthusiastic and motivated individual to join our close-knit team where humour and mutual support are valued
Recruiter: Quakers Lane Surgery
Specialty Doctor in Musculoskeletal and Sport and Exercise Medicine
LeicesterWe are pleased to offer an opportunity to apply for one of our established GP/Speciality Dr posts working in the Leicester Hospital Sports Medicine
Recruiter: University Hospitals of Leicester NHS Trust
Southwark, London (Greater)We are looking for new GP Partners who will bring fresh ideas, enthusiasm and commitment to our partnership in Southwark.
Recruiter: Nexus Health Group
Consultant Geriatric Medicine
GuildfordLooking to appoint Consultant Geriatrician to work in our evolving Hospital at Home service. This is a substantive post.
Recruiter: The Royal Surrey NHS Foundation Trust